CN101925590A - 治疗成瘾的aldh-2抑制剂 - Google Patents

治疗成瘾的aldh-2抑制剂 Download PDF

Info

Publication number
CN101925590A
CN101925590A CN200880125439XA CN200880125439A CN101925590A CN 101925590 A CN101925590 A CN 101925590A CN 200880125439X A CN200880125439X A CN 200880125439XA CN 200880125439 A CN200880125439 A CN 200880125439A CN 101925590 A CN101925590 A CN 101925590A
Authority
CN
China
Prior art keywords
phenyl
chromene
group
ketone
hydroxyphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880125439XA
Other languages
English (en)
Chinese (zh)
Inventor
雅罗斯拉夫·比洛金
埃尔法蒂赫·埃尔扎因
杰夫·扎布沃茨基
迈克尔·奥根
陶佩里
小林徹也
马修·阿贝尔曼
拉奥·卡拉
范培东
伊万·戴蒙德
罗伯特·江
马里亚·皮亚·阿罗尔福
李小芬
姚丽娜
江湛
姜永明
陶国新
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Palo Alto Inc
Original Assignee
CV Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CV Therapeutics Inc filed Critical CV Therapeutics Inc
Publication of CN101925590A publication Critical patent/CN101925590A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/34—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only
    • C07D311/36—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only not hydrogenated in the hetero ring, e.g. isoflavones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Addiction (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
CN200880125439XA 2008-01-24 2008-01-24 治疗成瘾的aldh-2抑制剂 Pending CN101925590A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2008/051862 WO2009094028A1 (en) 2008-01-24 2008-01-24 Aldh-2 inhibitors in the treatment of addiction

Publications (1)

Publication Number Publication Date
CN101925590A true CN101925590A (zh) 2010-12-22

Family

ID=39731733

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880125439XA Pending CN101925590A (zh) 2008-01-24 2008-01-24 治疗成瘾的aldh-2抑制剂

Country Status (13)

Country Link
EP (1) EP2254878A1 (enrdf_load_stackoverflow)
JP (1) JP2011510072A (enrdf_load_stackoverflow)
KR (1) KR20100130589A (enrdf_load_stackoverflow)
CN (1) CN101925590A (enrdf_load_stackoverflow)
AU (1) AU2008348372A1 (enrdf_load_stackoverflow)
BR (1) BRPI0822129A2 (enrdf_load_stackoverflow)
CA (1) CA2712750A1 (enrdf_load_stackoverflow)
EC (1) ECSP10010417A (enrdf_load_stackoverflow)
IL (1) IL207127A0 (enrdf_load_stackoverflow)
MA (1) MA32095B1 (enrdf_load_stackoverflow)
MX (1) MX2010008111A (enrdf_load_stackoverflow)
WO (1) WO2009094028A1 (enrdf_load_stackoverflow)
ZA (1) ZA201004671B (enrdf_load_stackoverflow)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102161648A (zh) * 2011-02-18 2011-08-24 中国药科大学 具有选择性雌激素受体调节活性的异黄酮类化合物的制备方法及其用途
CN103764640A (zh) * 2011-08-30 2014-04-30 吉利德科学股份有限公司 成瘾治疗中的aldh-2抑制剂
CN108276374A (zh) * 2018-03-29 2018-07-13 天津科技大学 黄酮类芳香化酶抑制剂及其制备方法与应用
WO2021097875A1 (zh) * 2019-11-21 2021-05-27 中国科学院宁波材料技术与工程研究所 一种基于天然黄酮类化合物的生物基本征阻燃环氧树脂前驱体及其制备方法和应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI567061B (zh) 2011-07-01 2017-01-21 吉李德科學股份有限公司 用於治療成癮之化合物
CA3077606A1 (en) * 2017-10-16 2019-04-25 Amygdala Neurosciences, Inc. Combination therapy for preventing addiction
EP4532016A2 (en) * 2022-05-31 2025-04-09 University of Maryland, Baltimore Aldh2 inhibitors and methods of use thereof
WO2023244574A1 (en) 2022-06-14 2023-12-21 Amygdala Neurosciences, Inc. Aldh-2 inhibitor compounds and methods of use
WO2023244563A1 (en) 2022-06-14 2023-12-21 Amygdala Neurosciences, Inc. Aldh-2 inhibitor compounds and methods of use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU162377B (enrdf_load_stackoverflow) * 1970-05-27 1973-02-28
US4166862A (en) * 1971-05-25 1979-09-04 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. Animal feed containing anabolic isoflavones
GB8626344D0 (en) * 1986-11-04 1986-12-03 Zyma Sa Bicyclic compounds
US5204369A (en) * 1991-07-01 1993-04-20 The Endowment For Research In Human Biology Method for the inhibition of aldh-i useful in the treatment of alcohol dependence or alcohol abuse
EP1077697B1 (en) * 1998-05-12 2006-07-19 The Endowment For Research In Human Biology, Inc. Methods and assays useful in the treatment of alcohol dependence or alcohol abuse
EP1524974A4 (en) * 2001-05-04 2007-12-05 Paratek Pharm Innc TRANSCRIPTION FACTOR MODULATING COMPOUNDS AND METHODS OF USE
AUPR957001A0 (en) * 2001-12-19 2002-01-24 Novogen Research Pty Ltd Isoflavone conjugates, derivatives thereof and therapeutic methods involving same
NZ537366A (en) * 2002-06-27 2007-12-21 Endowment For Res In Human Bio Compounds useful for the inhibition of ALDH
CA2571421A1 (en) * 2004-06-24 2006-01-05 Nicholas Valiante Compounds for immunopotentiation
PL377180A1 (pl) * 2005-09-21 2007-04-02 Instytut Farmaceutyczny Zastosowanie izoflawonów i ich pochodnych w leczeniu mukopolisacharydoz
EP2046769A2 (en) * 2006-07-27 2009-04-15 Cv Therapeutics, Inc. Aldh-2 inhibitors in the treatment of addiction
JP2011503095A (ja) * 2007-11-06 2011-01-27 ギリアード・パロ・アルト・インコーポレイテッド 精神障害の処置におけるａｌｄｈ−２インヒビター

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102161648A (zh) * 2011-02-18 2011-08-24 中国药科大学 具有选择性雌激素受体调节活性的异黄酮类化合物的制备方法及其用途
CN103764640A (zh) * 2011-08-30 2014-04-30 吉利德科学股份有限公司 成瘾治疗中的aldh-2抑制剂
CN108276374A (zh) * 2018-03-29 2018-07-13 天津科技大学 黄酮类芳香化酶抑制剂及其制备方法与应用
WO2021097875A1 (zh) * 2019-11-21 2021-05-27 中国科学院宁波材料技术与工程研究所 一种基于天然黄酮类化合物的生物基本征阻燃环氧树脂前驱体及其制备方法和应用

Also Published As

Publication number Publication date
BRPI0822129A2 (pt) 2015-06-23
AU2008348372A1 (en) 2009-07-30
MX2010008111A (es) 2010-11-30
ECSP10010417A (es) 2010-11-30
KR20100130589A (ko) 2010-12-13
IL207127A0 (en) 2010-12-30
CA2712750A1 (en) 2009-07-30
MA32095B1 (fr) 2011-02-01
JP2011510072A (ja) 2011-03-31
EP2254878A1 (en) 2010-12-01
ZA201004671B (en) 2011-03-30
WO2009094028A1 (en) 2009-07-30

Similar Documents

Publication Publication Date Title
CN101925590A (zh) 治疗成瘾的aldh-2抑制剂
CN100491371C (zh) 用作糖原合酶激酶3β抑制剂(GSK3抑制剂)的杂芳胺化合物
CN100404536C (zh) 作为糖原合酶激酶3抑制剂的三唑并嘧啶衍生物
CN108440515B (zh) 取代的苯并呋喃基和苯并噁唑基化合物及其用途
CN100436427C (zh) 用作糖原合酶激酶3β抑制剂的氨基苯甲酰胺衍生物
CN102176826B (zh) 取代的三唑并哒嗪衍生物
CN102485721B (zh) 取代的2,3-二氮杂萘酮化合物及其用途
EP2046769A2 (en) Aldh-2 inhibitors in the treatment of addiction
CN103635460A (zh) 用于治疗成瘾性的化合物
CN101917987A (zh) 治疗精神病障碍的aldh-2抑制剂
TW200526639A (en) Pyrazole derivatives and uses thereof
CN104080455A (zh) 某些化学实体、组合物及方法
JP2013525476A (ja) Ａｌｋ阻害剤としての複素環式誘導体
CN104341388A (zh) 芳香族酰胺类衍生物、其制备方法及其在医药上的应用
CA2930414A1 (en) Tetrahydroquinoline compositions as bet bromodomain inhibitors
CN101970440A (zh) 作为蛋白激酶抑制剂的2-氟吡唑并[1，5-a]嘧啶类
CN103097384A (zh) 取代的咪唑并[1,2-a]嘧啶和吡啶
CN101932584A (zh) 作为pi3k阻滞剂的吡咯并嘧啶衍生物及其用途
US7951813B2 (en) Quinazolinone derivatives as ALDH-2 inhibitors
TW201731841A (zh) 6‐芳基或6‐異芳基‐4‐嗎啉‐4‐芳基‐吡啶‐2‐酮化合物
CN101006065A (zh) 抑制bcl蛋白与结合伴侣的相互作用的化合物和方法
JP2017513847A (ja) ２，３，４，６−４置換ベンゼン−１，５−ジアミン誘導体、その製造方法および医薬品における使用
CN104837844A (zh) 作为酪蛋白激酶1 d/e抑制剂的吡唑取代的咪唑并哌嗪
AU2012300209B2 (en) ALDH-2 inhibitors in the treatment of addiction
CN101627024A (zh) 成瘾治疗中的aldh-2抑制剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20101222